Trending SEC Filings: Key Highlights from CERO, RHE, OTLC, and More

2 hours ago

Trending SEC Filings: Key Highlights from CERO, RHE, OTLC, and More
Generated image for illustrative purposes:

7 Highlights

  • CERO gets FDA approval for CER-1236 trials, boosting R&D focus.
  • CERO plans reverse stock split to address Nasdaq compliance.
    • Spindletop's revenue drops 22.3% from reduced oil and gas output.
    • Spindletop seeks joint ventures to solve capital issues.
    • Oncotelic pushes cancer drug research despite financial losses.
    • RHE faces challenges from CMS's new staffing mandate.
    • Spirits Time shifts to tequila marketing with no recent revenue.
0 Comments

0 Comments

Be the first to comment

Add your thoughts and get the conversation going.

Related Articles

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.